在激素受体阳性转移性乳腺癌中测序系统疗法:现代范式
Stephanie A Haddad1, Don S Dizon2, Stephanie L Graff2
1Kent Hospital Internal Medicine Residency Program, Brown University, Providence, RI, USA.
Chinese clinical oncology
|August 13, 2023
概括
激素受体阳性转移性乳腺癌 (HR+MBC) 治疗的进步提供了新的选择. 本综述指导了顺序治疗选择,考虑生存结果和副作用,以获得更好的患者护理.
科学领域:
- 在瘤学瘤学.
- 医学治疗学 医学治疗学
- 癌症研究 癌症研究
背景情况:
- 转移性乳腺癌,特别是激素受体阳性 (HR + MBC),仍然是女性癌症死亡的重要原因.
- 最近的治疗进展增加了HR+MBC的治疗复杂性,需要治疗的战略序列.
- 有效的管理需要了解不断变化的治疗场景和个性化的方法.
研究的目的:
- 审查HR+MBC目前的治疗模式,包括顺序治疗策略.
- 讨论新出现的治疗方案及其对生存和不良影响的影响.
- 为HR+ MBC提供治疗决策的逐步指南.
主要方法:
- 对HR+MBC治疗选择的当前文献的综述.
- 讨论不同治疗线路的诊断方法和管理.
- 探索向疗法,包括CDK4/6抑制剂,ADC和向PIK3CA,ESR1和PARP的药物.
主要成果:
- 对HR+ MBC的第一线和第二线管理策略的详细概述.
- 对内分泌阻燃性HR+MBC的治疗选择进行分析.
- 重点是整合基因/基因组测试和个人化治疗计划的共享决策.
结论:
- 连续治疗,包括新型药物和个性化药物,对于优化HR+ MBC的结果至关重要.
- 患者和医生之间的共同决策对于导航复杂的治疗选择至关重要.
- 持续的研究和对向治疗的理解将进一步完善HR + MBC管理.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K